THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is G8807B956. A total of 1 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $13,455 | -38.0% | 1,300 | -35.0% | 0.00% | – |
| Q1 2023 | $21,700 | +75.8% | 2,000 | +81.8% | 0.00% | – |
| Q4 2022 | $12,342 | -94.1% | 1,100 | -94.7% | 0.00% | – |
| Q3 2022 | $210,000 | +20900.0% | 20,700 | +20600.0% | 0.00% | – |
| Q2 2022 | $1,000 | -99.1% | 100 | -99.1% | 0.00% | – |
| Q1 2022 | $109,000 | -80.2% | 11,400 | -84.7% | 0.00% | -100.0% |
| Q3 2021 | $551,000 | +375.0% | 74,500 | +1390.0% | 0.00% | 0.0% |
| Q1 2020 | $116,000 | +123.1% | 5,000 | +150.0% | 0.00% | – |
| Q4 2019 | $52,000 | -95.9% | 2,000 | -97.4% | 0.00% | -100.0% |
| Q2 2019 | $1,254,000 | +10.6% | 76,800 | +53.6% | 0.01% | -15.4% |
| Q1 2019 | $1,134,000 | +22580.0% | 50,000 | +24900.0% | 0.01% | – |
| Q1 2018 | $5,000 | -96.6% | 200 | -95.3% | 0.00% | -100.0% |
| Q3 2017 | $147,000 | +83.8% | 4,300 | +72.0% | 0.00% | 0.0% |
| Q4 2016 | $80,000 | -87.1% | 2,500 | -85.4% | 0.00% | -85.7% |
| Q3 2016 | $620,000 | +684.8% | 17,100 | +388.6% | 0.01% | +600.0% |
| Q2 2016 | $79,000 | -92.0% | 3,500 | -96.1% | 0.00% | -92.9% |
| Q3 2015 | $989,000 | +6081.2% | 90,000 | +7400.0% | 0.01% | – |
| Q2 2015 | $16,000 | – | 1,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |